About Spinraza

  • The U.S. Food and Drug Administration approved Spinraza in December 2016, the first drug approved to treat children and adults with spinal muscular atrophy (SMA), a rare and often fatal genetic disease affecting muscle strength and movement.
  • Memorial Healthcare is one of five hospitals in the State of Michigan administrating Spinraza to adults, aged 15 years and older with the goal of treatment being able to stabilize the disease process
  • Spinraza is administered in partnership with interventional radiologists on an outpatient basis on the main campus of Memorial Healthcare
  • After its initial dose, Spinraza is given at 14-day intervals; with the 4th dose administered 30 days after the 3rd Maintenance doses are administered once every 4 months thereafter
  • Dr. Frey treated her first patient with Spinraza in December 2017. Early results have shown:
    • After just one treatment, a 23 year old patient has seen some improvement in muscle movement including being able to lift a glass and plate and roll from her back to her side
    • A patient in his 60’s, is now able to push an elevator button, something he hasn’t been able to do in quite some time

To learn more about SMA, visit CureSMA by clicking here.